Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × INDUSTRY × Neuroectodermal Tumors × Clear all

Phase

Status

Completed 5 Recruiting 2 Unknown 1 Approved for marketing 1

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 150 Carcinoma, Non-Small-Cell Lung 143 Breast Neoplasms 143 Colorectal Neoplasms 86 Stomach Neoplasms 72 Pancreatic Neoplasms 64 Prostatic Neoplasms 62 Lung Neoplasms 61 Melanoma 58 Neoplasm Metastasis 57 Carcinoma, Hepatocellular 56 Leukemia, Myeloid, Acute 55 Recurrence 53 Ovarian Neoplasms 52 Multiple Myeloma 52 Lymphoma 47 Advanced Solid Tumor 45 Advanced Solid Tumors 44 Solid Tumor 41 Uterine Cervical Neoplasms 38 Lymphoma, Non-Hodgkin 34 Colonic Neoplasms 34 Leukemia 33 Glioblastoma 33 Lymphoma, B-Cell 30 Head and Neck Neoplasms 26 Esophageal Neoplasms 26 Urinary Bladder Neoplasms 25 Precursor Cell Lymphoblastic Leukemia-Lymphoma 25 Lymphoma, Follicular 25

Interventions

Vorinostat 1 3-Iodobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03561259 2023-02-16

OPTIMUM

Jubilant DraxImage Inc.

Phase 2 Unknown

Neoplasms, Neuroblastoma, Neuroectodermal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡